Adrenal Androgens and Intracrinology

ABSTRACT

In postmenopausal women, all estrogens and nearly all androgens are made locally in peripheral target tissues from the inactive adrenal steroid precursor dehydroepiandrosterone (DHEA). In adult men, approximated 50% of androgens are made locally. This new section of endocrinology, which describes the local formation of sex steroids, has been named intracrinology. In fact, all the enzymes required to make androgens and estrogens are expressed in a cell-specific fashion, thus permitting local control of steroid formation and action. The local inhibition of sex steroid formation or action has shown important benefits in the treatment of hormone-sensitive cancers, including significant prolongation of survival and even curing localized disease. On the other hand, exogenous DHEA provides important advantages in postmenopausal women because it compensates for the declining secretion of DHEA by the adrenals with age. The benefits of DHEA include increased bone mineral density, muscle mass, well-being, and libido, as well as beneficial effects against skin atrophy, type 2 diabetes, and obesity.

KEYWORDS

Intracrinology - androgens - estrogens - peripheral target tissues

REFERENCES

• 1 Labrie F. Intracrinology.  Mol Cell Endocrinol. 1991;  78 C113-C118
• 2 Labrie F, Bélanger A, Simard J, Luu-The V, Labrie C. DHEA and peripheral androgen and estrogen formation. Intracrinology.  Ann N Y Acad Sci. 1995;  774 16-28
• 3 Labrie F, Simard J, Luu-The V et al.. The 3b-hydroxysteroid dehydrogenase/isomerase gene family: lessons from type II 3b-HSD congenital deficiency. In: Hansson V, Levy FO, Taskén K Signal Transduction in Testicular Cells. Ernst Schering Research Foundation Workshop New York; Springer-Verlag 1996: 185-218
• 4 Labrie F, Luu-The V, Lin S X et al.. The key role of 17b-HSDs in sex steroid biology.  Steroids. 1997;  62 148-158
• 5 Labrie C, Bélanger A, Labrie F. Androgenic activity of dehydroepiandrosterone and androstenedione in the rat ventral prostate.  Endocrinology. 1988;  123 1412-1417
• 6 Migeon C J, Keller A R, Lawrence B, Shepart II T H. Dehydroepiandrosterone and androsterone levels in human plasma. Effect of age and sex: day-to-day and diurnal variations.  J Clin Endocrinol Metab. 1957;  17 1051-1062
• 7 Vermeulen A, Verdonck L. Radioimmunoassays of 17b-hydroxy-5a-androstan-3-one, 4-androstene-3,17-dione, dehydroepiandrosterone, 17b-hydroxyprogesterone and progesterone and its application to human male plasma.  J Steroid Biochem. 1976;  7 1-10
• 8 Vermeulen A, Deslypene J P, Schelfhout W, Verdonck L, Rubens R. Adrenocortical function in old age: response to acute adrenocorticotropin stimulation.  J Clin Endocrinol Metab. 1982;  54 187-191
• 9 Orentreich N, Brind J L, Rizer R L, Vogelman J H. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood.  J Clin Endocrinol Metab. 1984;  59 551-555
• 10 Bélanger A, Candas B, Dupont A et al.. Changes in serum concentrations of conjugated and unconjugated steroids in 40- to 80-year-old men.  J Clin Endocrinol Metab. 1994;  79 1086-1090
• 11 Coleman D L, Leiter E H, Schwizer R W. Therapeutic effects of dehydroepiandrosterone (DHEA) in diabetic mice.  Diabetes. 1982;  31 830-833
• 12 Schriock E D, Buffington C K, Hubert G D et al.. Divergent correlations of circulating dehydroepiandrosterone sulfate and testosterone with insulin levels and insulin receptor binding.  J Clin Endocrinol Metab. 1988;  66 1329-1331
• 13 Nestler J E, Barlascini C O, Clore J N, Blackard W G. Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in normal men.  J Clin Endocrinol Metab. 1988;  66 57-61
• 14 MacEwen E G, Kurzman I D. Obesity in the dog: role of the adrenal steroid dehydroepiandrosterone (DHEA).  J Nutr. 1991;  121 S51-S55
• 15 Tchernof A, Després J P, Bélanger A et al.. Reduced testosterone and adrenal C19 steroid levels in obese men.  Metabolism. 1995;  44 513-519
• 16 Morales A J, Nolan J J, Nelson J C, Yen S S. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age.  J Clin Endocrinol Metab. 1994;  78 1360-1367
• 17 Baulieu E E, Thomas G, Legrain S et al.. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue.  Proc Natl Acad Sci USA. 2000;  97 4279-4284
• 18 Diamond P, Cusan L, Gomez J L, Bélanger A, Labrie F. Metabolic effects of 12-month percutaneous DHEA replacement therapy in postmenopausal women.  J Endocrinol. 1996;  150 S43-S50
• 19 Labrie F, Diamond P, Cusan L, Gomez J L, Bélanger A. Effect of 12-month DHEA replacement therapy on bone, vagina, and endometrium in postmenopausal women.  J Clin Endocrinol Metab. 1997;  82 3498-3505
• 20 Buzdar A U, Smith R, Vogel C et al.. Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of post-menopausal patients with metastatic breast carcinoma: results of 2 randomized double-blind controlled multiinstitutional trials.  Cancer. 1996;  77 2503-2513
• 21 Cummings S R, Eckert S, Krueger K A et al.. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.  JAMA. 1999;  281 2189-2197
• 22 Peltoketo H, Isomaa V, Mäentausta O, Vihko R. Complete amino acid sequence of human placental 17b-hydroxysteroid dehydrognease deduced from cDNA.  FEBS Lett. 1988;  239 73-77
• 23 Luu-The V, Labrie C, Zhao H F et al.. Characterization of cDNAs for human estradiol 17b-dehydrogenase and assignment of the gene to chromosome 17: evidence of two mRNA species with distinct 5Ž termini in human placenta.  Mol Endocrinol. 1989;  3 1301-1309
• 24 Geissler W M, Davis D L, Wu L et al.. Male pseudohermaphroditism caused by mutations of testicular 17b-hydroxysteroid dehydrogenase 3.  Nat Genet. 1994;  7 34-39
• 25 Luu-The V. Analysis and characteristics of multiple types of human 17beta-hydroxysteroid dehydrogenase.  J Steroid Biochem Mol Biol. 2001;  76 143-151
• 26 Labrie F, Luu-The V, Labrie C et al.. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone.  Endocr Rev. 2003;  24 152-182
• 27 Dufort I, Rheault P, Huang X F, Soucy P, Luu-The V. Characteristics of a highly labile human type 5 17beta-hydroxysteroid dehydrogenase.  Endocrinology. 1999;  140 568-574
• 28 El-Alfy M, Luu-The V, Huang X F et al.. Localization of type 5 17b-hydroxysteroid dehydrogenase, 3 b-hydroxysteroid dehydrogenase and androgen receptor in the human prostate by in situ hybridization and immunocytochemistry.  Endocrinology. 1999;  140 1481-1491
• 29 Pelletier G, Luu-The V, El-Alfy M, Li S, Labrie F. Immunoelectron microscopic localization of 3b-hydroxysteroid dehydrogenase and type 5 17b-hydroxysteroid dehydrogenase in the human prostate and mammary gland.  J Mol Endocrinol. 2001;  26 11-19
• 30 Nokelainen P, Peltoketo H, Vihko R, Vihko P. Expression cloning of a novel estrogenic mouse 17 beta-hydroxysteroid dehydrogenase/17-ketosteroid reductase (m17HSD7), previously described as a prolactin receptor-associated protein (PRAP) in rat.  Mol Endocrinol. 1998;  12 1048-1059
• 31 He X Y, Merz G, Mehta P, Schulz H, Yang S Y. Human brain short chain L-3-hydroxyacyl coenzyme A dehydrogenase is a single-domain multifunctional enzyme. Characterization of a novel 17beta-hydroxysteroid dehydrogenase.  J Biol Chem. 1999;  274 15014-15019
• 32 Brereton P, Suzuki T, Sasano H et al.. Pan1b (17betaHSD11)-enzymatic activity and distribution in the lung.  Mol Cell Endocrinol. 2001;  171 111-117
• 33 Napoli J L. 17beta-Hydroxysteroid dehydrogenase type 9 and other short-chain dehydrogenases/reductases that catalyze retinoid, 17beta- and 3alpha-hydroxysteroid metabolism.  Mol Cell Endocrinol. 2001;  171 103-109
• 34 Cheng K C, White P C, Qin K N. Molecular cloning and expression of rat liver 3 alpha-hydroxysteroid dehydrogenase.  Mol Endocrinol. 1991;  5 823-828
• 35 Dufort I, Tremblay Y, Bélanger A, Labrie F, Luu-The V. Isolation and characterization of a stereospecific 3b-hydroxysteroid sulfotransferase (pregnenolone sulfotransferase) cDNA.  DNA Cell Biol. 1996;  15 481-487
• 36 Hudson R W. Comparison of 3 alpha-hydroxysteroid dehydrogenase activities in the microsomal fractions of hyperplastic, malignant and normal human prostatic tissues.  J Steroid Biochem. 1984;  20 829-833
• 37 Labrie F, Bélanger A, Cusan L, Gomez J L, Candas B. Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging.  J Clin Endocrinol Metab. 1997;  82 2396-2402
• 38 Labrie F, Belanger A, Cusan L, Candas B. Physiological changes in dehydroepiandrosterone are not reflected by serum levels of active androgens and estrogens but of their metabolites: intracrinology.  J Clin Endocrinol Metab. 1997;  82 2403-2409
• 39 Riggs B L, Wahner H W, Dunn W L et al.. Differential changes in bone mineral density of the appendicular and axial skeleton with aging: relationship to spinal osteoporosis.  J Clin Invest. 1981;  67 328-335
• 40 Mazess R B. On aging bone loss.  Clin Orthop. 1982;  165 239-252
• 41 Johnston Jr C C, Hui S L, Witt R M et al.. Early menopausal changes in bone mass and sex steroids.  J Clin Endocrinol Metab. 1985;  61 905-911
• 42 Zumoff B, Strain G W, Miller L K, Rosner W. Twenty-four-hour mean plasma testosterone concentration declines with age in normal premenopausal women.  J Clin Endocrinol Metab. 1995;  80 1429-1430
• 43 Grodin J M, Siiteri P K, McDonald P C. Source of estrogen production in postmenopausal women.  J Clin Endocrinol Metab. 1973;  36 207-214
• 44 Steinberg K K, Freni-Titulaer L W, DePuey E G et al.. Sex steroids and bone density in premenopausal and perimenopausal women.  J Clin Endocrinol Metab. 1989;  69 533-539
• 45 Lobo R A. Androgens in postmenopausal women: production, possible role, and replacement options.  Obstet Gynecol Surv. 2001;  56 361-376
• 46 Sherwin B B, Gelfand M M. Differential symptom response to parenteral estrogen and/or androgen administration in the surgical menopause.  Am J Obstet Gynecol. 1985;  151 153-160
• 47 Sherwin B B. Affective changes with estrogen and androgen replacement therapy in surgically menopausal women.  J Affect Disord. 1988;  14 177-187
• 48 Notelovitz M, Watts N, Timmons C et al.. Effects of Estrogen Plus Low Dose Androgen Versus Estrogen Alone on Menopausal Symptoms in Oophorectomized/Hysterectomized Women. Montreal; North American Menopause Society 1991
• 49 Leiblum S, Bachmann G, Kemmann E, Colburn D, Swartzman L. Vaginal atrophy in the postmenopausal women. The importance of sexual activity and hormones.  JAMA. 1983;  249 2195-2198
• 50 Sherwin B B, Gelfand M M. The role of androgen in the maintenance of sexual functioning in oophorectomized women.  Psychosom Med. 1987;  49 397-409
• 51 Pye J K, Mansel R E, Hughes L E. Clinical experience of drug treatments for mastalgia.  Lancet. 1985;  2 373-377
• 52 DeFazio J, Meldrum D R, Winer J H, Judd H L. Direct action of androgen on hot flushes in the human male.  Maturitas. 1984;  6 3-8
• 53 Sherwin B B, Gelfand M M. Effects of parenteral administration of estrogen and androgen on plasma hormone levels and hot flushes in the surgical menopause.  Am J Obstet Gynecol. 1984;  148 552-557
• 54 Schwartz A G, Pashko L, Whitcomb J M. Inhibition of tumor development by dehydroepiandrosterone and related steroids.  Toxicol Pathol. 1986;  14 357-362
• 55 Gordon G B, Shantz L M, Talalay P. Modulation of growth, differentiation and carcinogenesis by dehydroepiandrosterone.  Adv Enzyme Regul. 1987;  26 355-382
• 56 Li S, Yan X, Bélanger A, Labrie F. Prevention by dehydroepiandrosterone of the development of mammary carcinoma induced by 7,12-dimethylbenz(a)anthracene (DMBA) in the rat.  Breast Cancer Res Treat. 1993;  29 203-217
• 57 Suzuki T, Suzuki N, Daynes R A, Engleman E G. Dehydroepiandrosterone enhances IL2 production and cytotoxic effector function of human T cells.  Clin Immunol Immunopathol. 1991;  61 202-211
• 58 Rasmussen K R, Arrowood M J, Healey M C. Effectiveness of dehydroepiandrosterone in reduction of cryptosporidial activity in immunosuppressed rats.  Antimicrob Agents Chemother. 1992;  36 220-222
• 59 Henderson E, Yang J Y, Schwartz A. Dehydroepiandrosterone (DHEA) and sysnthetic DHEA analogs are modest inhibitors of HIV-1 IIIB replication.  AIDS Res Hum Retroviruses. 1992;  8 625-631
• 60 Casson P R, Andersen R N, Herrod H G et al.. Oral dehydroepiandrosterone in physiologic doses modulates immune function in postmenopausal women.  Am J Obstet Gynecol. 1993;  169 1536-1539
• 61 Labrie F, Luu-The V, Lin S-X, Simard J, Labrie C. Role of 17b-hydroxysteroid dehydrogenases in sex steroid formation in peripheral intracrine tissues.  Trends Endocrinol Metab. 2000;  11 421-427
• 62 Labrie F, Dupont A, Bélanger A et al.. New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen.  Clin Invest Med. 1982;  5 267-275
• 63 Labrie F, Dupont A, Bélanger A. Complete androgen blockade for the treatment of prostate cancer. In: de Vita VT, Hellman S, Rosenberg SA Important Advances in Oncology Philadelphia; J.B. Lippincott 1985: 193-217
• 64 Crawford E D, Eisenberger M A, McLeod D G et al.. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.  N Engl J Med. 1989;  321 419-424
• 65 Denis L, Carnelro de Moura J, Bono A et al.. Goserelin acetate and flutamide vs bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center.  Urology. 1993;  42 119-129
• 66 Bennett C L, Tosteson T D, Schmitt B et al.. Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: a meta-analysis of nine published randomized controlled trials and 4128 patients using Flutamide.  Prostate Cancer Prostatic Dis. 1999;  2 4-8
• 67 Klotz L. Combined androgen blockade in prostate cancer: meta-analyses and associated issues.  BJU Int. 2001;  87 806-813
• 68 Schmitt B, Wilt T J, Schellhammer P F et al.. Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review.  Urology. 2001;  57 727-732
• 69 Aprikian A G, Fleshner N, Langleben A, Hames J. An oncology perspective on the benefits and cost of combined androgen blockade in advanced prostate cancer.  Can J Urol. 2003;  10 1986-1994
• 70 Klotz L H. Selling ourselves short.  Can J Urol. 2003;  10 1969
• 71 Janknegt R A, Abbou C C, Bartoletti R et al.. Orchiectomy and Nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial.  J Urol. 1993;  149 77-83
• 72 Caubet J F, Tosteson T D, Dong E W et al.. Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens.  Urology. 1997;  49 71-78
• 73 Dijkman G A, Janknegt R A, Dereijke T M, Debruyne F MJ. Long-term efficacy and safety of nilutamide plus castration in advanced prostate-cancer, and the significance of early prostate specific antigen normalization.  J Urol. 1997;  158 160-163
• 74 Denis L J, Keuppens F, Smith P H et al.. Maximal androgen blockade: final analysis of EORTC Phase III trial 30853.  Eur Urol. 1998;  33 144-151
• 75 Prostate Cancer Trialists' Collaborative Group . Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials.  Lancet. 2000;  355 1491-1498
• 76 Debruyne F, Delaere P, Vander Poorten V. Postoperative course of serum parathyroid hormone and calcium after surgery for primary hyperparathyroidism.  Acta Otorhinolaryngol Belg. 2001;  55 153-157
• 77 Labrie F, Bélanger A, Cusan L et al.. History of LHRH agonists and combination therapy in prostate cancer.  Endocr Relat Cancer. 1996;  3 243-278
• 78 Labrie F, Candas B, Gomez J L, Cusan L. Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer?.  Urology. 2002;  60 115-119
• 79 Labrie F, Champagne P, Labrie C et al.. Activity and safety of the orally active pure antiestrogen EM-800 (SCH 57050) in Tamoxifen-resistant breast cancer.  J Clin Oncol. 2004;  22 864-871
• 80 Thompson I M, Goodman P J, Tangen C M et al.. The influence of finasteride on the development of prostate cancer.  N Engl J Med. 2003;  349 215-224
• 81 Soloway M S, Ishikawa S, Van der Zwang R, Todd B. Prognostic factors in patients with advanced prostate cancer.  Urology. 1989;  33 53-56
• 82 Leibowitz R L, Tucker S J. Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients.  Oncologist. 2001;  6 177-182